An Intravenous Pancreatic Cancer Therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic Supplementary Information Histology Slides Part 4
<p>H&E and Gram stained whole slide scans for blinded cohorts from publication titled ‘An Intravenous Pancreatic Cancer Therapeutic: Characterization of CRISPR/Cas9n-modified <em>Clostridium novyi-</em>Non Toxic’ published in PLOS One 2023.</p> <p>Excerpt from methods section of publication detailing acquisition of this data: "Formalin-fixed tissue samples were processed for paraffin embedding by the means of dehydration, clearing and paraffin infiltration (Lynx II Tissue Processor). The paraffin embedded tissue samples were sectioned using a Leica Rotatory Microtome RM2125 RTS at 5um thickness. Designated tissue sections were subsequently de-paraffined and stained with H&E and gram staining as per standard histology protocols (Leica Autostainer XL). Whole slide scanning (WSI) was performed by a Panoramic 250 whole slide scanner at 20x magnification (3D Histech) using a Carl-Zeiss Plan-Apochromat 20x / NA 0.8 objective."</p> <p>Please note when downloading the image files that the folder containing all of the .data files <strong>cannot</strong> contain the corresponding .mxrs file. The .mxrs and the folder containing the .data files <strong>must</strong> have identical names and be at the same file level (as uploaded). Files of this type can be opened by the open source software FIJI or QuPath, among others.</p> <p>Cohorts have been uploaded with viewers blinded to treatment groups to allow for unbiased review should it be desired, with a cohort key uploaded separately (doi: ##). Files are grouped so that all major organs from a single mouse are in the same compressed folder.</p>
ShareScore
40/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 4
- Harmonization
- 4
- Access
- 16
- Reuse readiness
- 8
- Engagement
- 8